Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2026)

Rani Therapeutics Holdings' Interest Expenses history spans 7 years, with the latest figure at $88000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses fell 90.67% to $88000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.0 million, a 56.47% decrease, with the full-year FY2025 number at $2.9 million, down 42.56% from a year prior.
  • Interest Expenses came in at $88000.0 for Q1 2026, down from $347000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $1.3 million in Q3 2024, with the low at $88000.0 in Q1 2026.
  • Historically, Interest Expenses has averaged $944466.7 across 5 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Interest Expenses: soared 72000.0% in 2022 and later crashed 90.67% in 2026.
  • Year by year, Interest Expenses stood at $719000.0 in 2022, then surged by 80.25% to $1.3 million in 2023, then dropped by 13.27% to $1.1 million in 2024, then crashed by 69.13% to $347000.0 in 2025, then tumbled by 74.64% to $88000.0 in 2026.
  • Business Quant data shows Interest Expenses for RANI at $88000.0 in Q1 2026, $347000.0 in Q4 2025, and $725000.0 in Q3 2025.